Daily Roundup

CSL Makes Major Play in Rare Disease Treatment

CSL Ltd. has entered an exclusive partnership with Alentis Therapeutics to develop and commercialize lixudebart, a potential first-in-class treatment for rare kidney and liver diseases. The biopharmaceutical giant is putting serious money behind the deal, committing an initial US$355 million upfront with up to an additional US$1.2 billion tied to commercial milestones.

The focus is on advancing lixudebart through clinical trials for several conditions, including ANCA-associated vasculitis, rapidly progressive glomerulonephritis, focal segmental glomerulosclerosis, and primary sclerosing cholangitis. CSL will shoulder the funding for the ongoing Phase 2 RENAL trial and planned Phase 3 studies, while both companies will share future profits from the treatment's commercialization.

Gold Miners Post Solid Production Numbers

On the mining front, gold producers are delivering steady results. PDI Gold reported 52,866 ounces of gold poured during the September quarter, with its Kiniero plant running above nameplate capacity and achieving impressive 88.3% gold recoveries. The operation milled 2.3 million tonnes of ore, though production at the Nampala site was hampered by ore access issues related to pit cutback activities. The company finished the quarter with US$405 million in cash and bullion.

Capricorn Metals also hit its marks, producing 31,218 ounces in the quarter and completing its Karlawinda Expansion Project on schedule and within budget. The expansion boosts processing capacity to 6.5 million tonnes per annum, positioning the company to reach 150,000 ounces of annual production. Capricorn remains on track for FY27 guidance of 137,000 to 147,000 ounces at an all-in sustaining cost of US$1,900 to US$2,100 per ounce.

Healthcare Innovation Gains Traction

In medical devices, Aroa Biosurgery's Symphony product is showing real promise for treating diabetic foot ulcers. Results from a randomized controlled trial published in the International Wound Journal demonstrate that adding Symphony to standard care significantly accelerates healing. The trial found that 55% of patients achieved complete wound closure within 12 weeks compared to just 35% with standard care alone. Even more impressive, the mean healing time dropped by 7.8 days—from 73.2 days down to 65.4 days.

Meanwhile, Dimerix marked a meaningful milestone as the first patient completed four years in its DMX-200 clinical program for focal segmental glomerulosclerosis. The achievement reflects strong patient commitment, with over 90% of those who finished the two-year Phase 3 ACTION3 trial choosing to continue into the two-year Open Label Extension study. This sustained engagement provides valuable long-term safety and efficacy data that could support future regulatory approvals.

Exploration Results Point to Deeper Gold Potential

Predictive Discovery's exploration team at the Kiniéro Gold Project has uncovered encouraging high-grade results at depth beneath existing deposits. Notable intercepts include 28.35 metres grading 5.87 grams per tonne of gold, suggesting the veins form part of a larger interconnected system. The company plans to significantly ramp up drilling next year, targeting approximately 1,800 holes across 140,000 metres to unlock additional mineral resource potential and extend mine life.